Back to News
Market Impact: 0.3
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Both doses of SPY072 reported statistically significant improvement versus placebo on at least one primary endpoint (change from baseline in DAS28-CRP) and key secondary endpoint (ACR20), with additional positive signals on exploratory measures such as ACR50.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Why is T-Mobile stock tumbling today?
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- The AI race may be decided by financing—not just better chips
- Why is Verizon stock sliding today?
- Wall St futures gain as oil slips; telecoms pressured by SpaceX spectrum deal
- OpenAI projected to bring in $20bn less in revenue than expected